In addition to these approaches, other dual-targeting strategies for HCC treatment are being explored to address antigen escape and the challenges posed by tumor microenvironment, such as targeting c-Met/PD-L1 and CD133/GPC3 94, 96. The gene discussed is MET; the disease is neoplasm.